SBR759 is a novel polynuclear iron(III) oxide-hydroxide starch·sucrose·carbonate complex being developed for oral use in chronic kidney disease (CKD) patients with hyperphosphatemia on hemodialysis. SBR759 binds inorganic phosphate released by food uptake and digestion in the gastro-intestinal tra
Ever since the introduction of EPO, ESAs and iron dosing have been driven by financial incentives. When ESAs were a profit center for providers, large doses were used. With ESAs becoming a cost center, a new trend has appeared, gradually replacing their use with iron to achieve the same therapeutic
The article deals with the results of examination of 51 neonatal infants born with extreme low body mass in terms of gestation 22-31 week at first day of life and in 38-40 weeks of post conception age. The study established lowering of both values of indicators of erythrocyte sprout and level of iro
ferrokinetics [fer″o-kĭ-net´iks] the turnover or rate of movement of iron in the body from plasma transferrin to erythrocyte precursors in the bone marrow to circulating erythrocytes to macrophages in the reticuloendothelial system and ...